Schizophrenia Research
Volume 120, Issue 1 , Pages 95-100 , July 2010

Cannabis use disorders in schizophrenia: Effects on cognition and symptoms

  • Pamela DeRosse

      Affiliations

    • Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    • Division of Psychiatry Research, The Zucker Hillside Hospital, Division of the North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA
    • Corresponding Author InformationCorresponding author. The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA. Tel.: +1 718 470 8601; fax: +1718 343 1659.
    • ,
  • Alyson Kaplan

      Affiliations

    • Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    • Princeton University, USA
    • ,
  • Katherine E. Burdick

      Affiliations

    • Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    • Division of Psychiatry Research, The Zucker Hillside Hospital, Division of the North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA
    • Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA
    • ,
  • Todd Lencz

      Affiliations

    • Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    • Division of Psychiatry Research, The Zucker Hillside Hospital, Division of the North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA
    • Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA
    • ,
  • Anil K. Malhotra

      Affiliations

    • Center for Translational Psychiatry, The Feinstein Institute for Medical Research, Manhasset, NY, USA
    • Division of Psychiatry Research, The Zucker Hillside Hospital, Division of the North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA
    • Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA

Received 1 February 2010 ,Revised 9 April 2010 ,Accepted 12 April 2010.

References 

  1. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 1999;25(1):173–182
  2. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5year follow-up study. Schizophr. Res. 2000;44(1):47–56
  3. Agrawal A, Lynskey MT. Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the national epidemiological survey on alcohol and related conditions. Drug. Alcohol Depend. 2007;88:300–307
  4. Andréasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;2:1483–1486
  5. Arias Horcajadas F, Romero SS, Calo JJP. Relevance of drug use in clinical manifestations of schizophrenia. Actas. Esp. Psiquiatr. 2002;30:65–73
  6. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br. J. Psychiatry. 2005;187:510–515
  7. Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis induced psychosis and schizophrenia. Arch. Gen. Psychiatry. 2008;65:1269–1274
  8. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry. 2004;184:110–117
  9. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry. 2006;188:237–242
  10. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009;35(2):383–402
  11. Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res. 2001 Mar 1;48(1):69–82.
  12. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur. Arch. Psychiatry. Clin. Neurosci. 1999;249:45–49
  13. Chen KW, Killeya-Jones LA. Understanding differences in marijuana use among urban Black and suburban White high school students from two U.S. community samples. J. Ethn. Subst. Abuse. 2006;5(2):51–73
  14. Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J. Affect Disord. 2008;106:109–117
  15. Cohen AS, Forbes CB, Mann MC, Blanchard JJ. Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. Schizophr. Res. 2006;81(2–3):227–238
  16. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr. Res. 2004;71(1):61–64
  17. Craddock N, Owen MJ. Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry. 2007;6:84–91
  18. Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol. Med. 2007;37:927–934
  19. DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, et al. Dysbindin (DTNBP1) genotype and negative symptoms in schizophrenia.. Am. J. Psychiatry. 2006;163(3):532–534
  20. DeRosse P, Hodgkinson CA, Lencz T, Burdick KE, Kane JM, Goldman D, et al. Disrupted in Schizophrenia 1 (DISC1) genotype and positive symptoms in schizophrenia. Biol. Psychiatry. 2007;61(10):1208–1210
  21. DeRosse P, Lencz T, Burdick KE, Siris SG, Kane JM, Malhotra AK. The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr. Bull. 2008;34:1047–1053
  22. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol. Med. 2003;33:15–21
  23. Grech A, van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur. Psychiatry. 2005;20:349–353
  24. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 2004;66:125–135
  25. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N Z J Psychiatry. 2000;34:468–475
  26. Harvey PD, Keefe RS, Patterson TL, Heaton RK, Bowie CR. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J. Clin. Exp. Neuropsychol. 2009;31(4):462–471
  27. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330:11–16
  28. Hollingshead, A.B. 1975. Four-factor Index of Social Status. Unpublished Manuscript, Yale University, New Haven, CT.
  29. Jockers-Scherübl MC, Wolf T, Radzei N, et al. Cannabis induced different cognitive changes in schizophrenic patients and in healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31:1054–1063
  30. Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 2003;63(3):297–299
  31. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry. 2005;57(6):688–691
  32. Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2009;Apr 22. Electronic publication ahead of print
  33. Kumra S, Thaden E, DeThomas C, Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr. Res. 2005;73:369–371
  34. Levinson DF, Mowry BJ. Defining the schizophrenia spectrum: issues for genetic linkage studies. Schizophr. Bull. 1991;17:491–514
  35. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr. Bull. 2009;35(3):493–508
  36. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579–1588
  37. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328
  38. Mortensen EL, Sørensen HJ, Jensen HH, Reinisch JM, Mednick SA. IQ and mental disorder in young men. Br. J. Psychiatry. 2005;187:407–415
  39. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta. Psychiatr. Scand. 1992;85(2):127–130
  40. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry. 2001;58:909–915
  41. Sevy S, Burdick KE, Visweswaraiah H, et al. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr. Res. 2007;92:74–84
  42. Sevy S, Robinson DG, Solloway S, et al. Correlates of substance misuse in patients with first episode schizophrenia and schizoaffective disorder. Acta. Psychiatrica. Scand. 2001;104:367–374
  43. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99:1333–1341
  44. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 2005;75:135–137
  45. van Os J, Bak M, Hanssen M, Bijl RV, de Graff R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002;156:319–327
  46. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age of onset of schizophrenia. Am. J. Psychiatry. 2004;161:501–506
  47. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet. 2002;114:949–955
  48. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325:1199–1204

PII: S0920-9964(10)01260-0

doi: 10.1016/j.schres.2010.04.007

Schizophrenia Research
Volume 120, Issue 1 , Pages 95-100 , July 2010

Article Tools